



in association with
USGA[®]

U.S. Women's Open – Drug Testing Process

Compliance with the drug testing program is a condition of entry to the championship. Any player who refuses to participate in the testing process may be disqualified and subject to sanctions.

Drug testing at the U.S. Women's Open will be administered in cooperation with the LPGA's Anti-Doping Program Protocol.

- The Anti-Doping Protocol, Prohibited Substance List, Drugs of Abuse List, Permitted Mediations List, and Therapeutic Use Exemption (TUE) Application and Procedures are all separately identified on <http://www.lpga.com/anti-doping-information>.
- **All TUE requests should be submitted in accordance with the LPGA Procedures and submitted to the LPGA no later than five (5) days after having been notified that you have been accepted into sectional qualifying, or within ten (10) days of having received an exemption to play in the U.S. Women's Open Championship.**

Questions regarding the LPGA Anti-Doping Protocol or TUE Process should be directed to the LPGA's Program Administrator at (386) 274-6201 or Emily.Lekahal@lpga.com. Questions regarding particular substances, including dietary supplements and vitamins should be addressed to the LPGA Drug Reference Hotline at 1-877-285-1436 or at drugtesting@lpga.com.

General questions regarding the USGA's Anti-Doping Policy can be directed to the USGA's Anti-Doping Program Administrator at (908) 326-1910.

**For the avoidance of doubt, the application of this Policy is for all participants in the championship proper, regardless of whether or not you are a member of the LPGA.*